Precision BioSciences, Inc. (DTIL)
| Market Cap | 182.69M |
| Revenue (ttm) | 34.26M |
| Net Income (ttm) | -45.72M |
| Shares Out | 25.80M |
| EPS (ttm) | -3.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,864 |
| Open | 7.10 |
| Previous Close | 7.04 |
| Day's Range | 7.03 - 7.19 |
| 52-Week Range | 3.53 - 8.82 |
| Beta | 1.09 |
| Analysts | Strong Buy |
| Price Target | 45.00 (+535.59%) |
| Earnings Date | May 14, 2026 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price target is $45.0, which is an increase of 535.59% from the latest price.
News
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference
ARCUS gene editing platform underpins two lead programs: PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy. Early clinical and preclinical data show promising efficacy and safety, with key data readouts expected in 2026 and a strong cash runway through 2028.
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company highlighted progress in its ARCUS-based gene editing programs for DMD and HBV, with IND clearance for DMD and plans to treat 3-5 patients in 2024. Early data from both programs show promising efficacy and safety, with further clinical results expected by year-end.
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: Sidoti's Year End Virtual Investor Conference
Two in-vivo gene editing programs are advancing: PBGENE-HBV for hepatitis B shows promising dose-dependent antiviral activity and sustained S antigen reduction, while PBGENE-DMD targets a large DMD patient segment with preclinical success. Financing supports milestones through 2028, with key data readouts expected in 2026.
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: Study Update
PBGENE-HBV demonstrated dose-dependent antiviral activity and a strong safety profile in phase I, with clinical biopsy confirming on-target gene editing and S antigen reduction. The program is advancing globally, supported by new funding, while the DMD program is on track for clinical entry in 2026.
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene e...
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: Chardan’s 9th Annual Genetic Medicines Conference
Genome editing is advancing with new platforms like ARCUS and engineered recombinases, enabling precise and durable gene insertion for a range of diseases. Clinical data show promise in severe pediatric and liver indications, with regulatory and investor support growing as the field moves toward broader applications and commercial viability.
Precision BioSciences Transcript: H.C. Wainwright Liver Disease Virtual Conference
The conference showcased the ARCUS gene editing platform, emphasizing its unique features and potential to achieve a complete cure for HBV by targeting cccDNA. Early clinical data show strong safety and promising antiviral activity, with further results and expanded studies expected soon.